Genprex Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors

Genprex, Inc. has announced that it has received a Notice of Allowance for a patent covering the use of its lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq. This patent will expire in 2037 at the earliest. The company has also been granted patents for the use of Reqorsa in combination with PD-L1 antibodies in Korea and PD-1 antibodies in several countries, including the US, Japan, and China. Genprex's REQORSA program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.

Key Takeaways:

Genprex has received a Notice of Allowance for a patent covering the use of its lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq.
The patent will expire in 2037 at the earliest.
Genprex has been granted patents for the use of Reqorsa in combination with PD-L1 antibodies in Korea, and PD-1 antibodies in the US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.
The patents cover the use of Reqorsa in combination with immune checkpoint inhibitors, including Tecentriq.
Genprex's REQORSA program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
The company is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel.
Genprex's REQORSA program has received Fast Track Designation from the FDA, and has also received FDA Orphan Drug Designation.

Statistics:

2037: The earliest expiration date of the patent for Reqorsa Gene Therapy in combination with PD-L1 antibodies.
7 countries: The US, Japan, Mexico, Russia, Australia, Chile, and China, where patents have been granted for the use of Reqorsa in combination with PD-1 antibodies.
2 clinical trials: The Acclaim-1 and Acclaim-2 clinical trials, which evaluate Genprex's lead product candidate, Reqorsa Gene Therapy, as a treatment for NSCLC and SCLC.
2 Fast Track Designations: Received by Genprex's lung cancer clinical programs, the Acclaim-1 and Acclaim-2 trials.

Sources:

Genprex, Inc. (Press Release, August 18, 2022)